Publication
NRAS-mutant melanoma: response to chemotherapy.
Authors not recorded
Arch Dermatol2011PMID 21576590stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerMelanomacivic_curation1.00
- drugTemozolomidecivic_curation1.00
- geneNRAScivic_curation1.00
- variantNRAS Q61Lcivic_curation1.00
- variantNRAS Q61Rcivic_curation1.00
Curated evidence
Evidence citing this paper (2)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 21576590
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| NRAS Q61L1 | ||||||||
| Temozolomide | Melanoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID22In a melanoma patient with NRAS Q61L mutation, treatment with temozolomide resulted in disease free survival of 14 months. PMID 21576590 · Soon et al., 2011 · Open in CIViC | civic |
| NRAS Q61R1 | ||||||||
| Temozolomide | Melanoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID23In a melanoma patient with Q61R mutation, treatment with temozolomide resulted in overall survival of 16 months. PMID 21576590 · Soon et al., 2011 · Open in CIViC | civic |